Skip to search formSkip to main contentSkip to account menu

satraplatin

Known as: (OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum, bis-acetatoamminedichlorocyclohexylamine platinum(IV), platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43) 
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Antineoplastic AgentsOrganoplatinum Compounds

Narrower (2)

BMS-182751JM 216
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation.
Platinum(II) anticancer drug cisplatin is one of the most important chemotherapeutic agents in clinical use but is limited by its… 
Highly Cited
2012
Highly Cited
2012
The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.
Highly Cited
2010
Highly Cited
2010
Photocytotoxic trans-diam(m)ine platinum(IV) diazido complexes more potent than their cis isomers.
The photocytotoxicity of a series of anticancer trans-dihydroxido [Pt(N(3))(2)(OH)(2)(NH(3))(X)] (X = alkyl or aryl amine… 
Review
2007
Review
2007
Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial
5019 Background: Chemotherapeutic options for HRPC are limited. S is a novel oral platinum compound. Methods: The SPARC trial is… 
Review
2006
Review
2006
Satraplatin: an orally available platinum analog for the treatment of cancer
Satraplatin is a novel, orally bioavailable, platinum anticancer drug. Platinum analogs form the mainstay of treatment for a… 
Review
2005
Review
2005
Future directions in the treatment of androgen-independent prostate cancer.
2002
2002
Direct addition of alcohols to organonitriles activated by ligation to a platinum(IV) center.
Treatment of trans-[PtCl(4)(RCN)(2)] (R = Me, Et) with R'OH (R' = Me, Et, n-Pr, i-Pr, n-Bu) at 45 degrees C in all cases allowed… 
Highly Cited
2000
Highly Cited
2000
Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione
Glutathione (GSH) reduction of the anticancer-active platinum(IV) compounds trans-[PtCl4(NH3)(thiazole)] (1), trans-[PtCl4(cha… 
Highly Cited
2000
Highly Cited
2000
Iminoacylation. 3. Formation of platinum(IV)-based metallaligands due to facile one-end addition of vic-dioximes to coordinated organonitriles.
The reaction of vic-dioximes with the organonitrile platinum(IV) complexes trans-[PtCl4(RCN)2] (R = Me, CH2Ph, Ph, vic-dioxime… 
Highly Cited
1980
Highly Cited
1980
Effects of second-generation platinum analogs on isolated PM-2 DNA and their cytotoxicity in vitro and in vivo.
Using PM-2 DNA and cytotoxicity assay systems, we have studied several second-generation platinum analogs and compared these to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)